Literature DB >> 8502298

The origin of HIV-1 isolate HTLV-IIIB.

S Y Chang1, B H Bowman, J B Weiss, R E Garcia, T J White.   

Abstract

The striking similarity between the first two human immunodeficiency virus type 1 (HIV-1) isolates Lai/LAV (formerly LAV, isolated at the Pasteur Institute) and Lai/IIIB (formerly HTLV-IIIB, reported to be isolated from a pooled culture at the Laboratory of Tumor Cell Biology (LTCB) of the National Cancer Institute) provoked considerable controversy in light of the high level of variability found among subsequent HIV-1 isolates. In November 1990, the Office of Scientific Integrity at the National Institutes of Health commissioned our group to analyse archival samples established at the Pasteur Institute and LTCB between 1983 and 1985. Retrospective analyses have shown that contamination of a culture derived from patient BRU by one from patient LAI was responsible for the provenance of HIV-1 Lai/LAV; the contaminated culture (M2T-/B) was sent to LTCB in September 1983. Our goals were to determine which HIV-1 variants were present in the samples and the sequence diversity among HIV-1 isolates from the earliest stages of the AIDS epidemic. We examined archival specimens and report here the detection of six novel HIV-1 sequences in the cultures used to establish the pool: none is closely related to HIV-1 Lai/IIIB. A sample derived from patient LAI contained variants of both HIV-1 Lai/IIIB and HIV-1 Lai/LAV, and a sequence identical to a variant of HIV-1 Lai/IIIB was detected in the contaminated M2T-/B culture. We conclude that the pool, and probably another LTCB culture, MoV, were contaminated between October 1983 and early 1984 by variants of HIV-1 Lai from the M2T-/B culture. Therefore, the origin of the HIV-1 Lai/IIIB isolate also was patient LAI.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8502298     DOI: 10.1038/363466a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  12 in total

Review 1.  Defining the molecular mechanisms of HIV-1 Tat secretion: PtdIns(4,5)P2 at the epicenter.

Authors:  Anthony R Mele; Jamie Marino; Kenneth Chen; Vanessa Pirrone; Chris Janetopoulos; Brian Wigdahl; Zachary Klase; Michael R Nonnemacher
Journal:  Traffic       Date:  2018-04-30       Impact factor: 6.215

2.  A method for determining the position and size of optimal sequence regions for phylogenetic analysis.

Authors:  M J Martin; F González-Candelas; F Sobrino; J Dopazo
Journal:  J Mol Evol       Date:  1995-12       Impact factor: 2.395

3.  CA Mutation N57A Has Distinct Strain-Specific HIV-1 Capsid Uncoating and Infectivity Phenotypes.

Authors:  Douglas K Fischer; Akatsuki Saito; Christopher Kline; Romy Cohen; Simon C Watkins; Masahiro Yamashita; Zandrea Ambrose
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

4.  Maintaining the integrity of human immunodeficiency virus sequence databases.

Authors:  G H Learn; B T Korber; B Foley; B H Hahn; S M Wolinsky; J I Mullins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Separation of human immunodeficiency virus type 1 replication from nef-mediated pathogenesis in the human thymus.

Authors:  K M Duus; E D Miller; J A Smith; G I Kovalev; L Su
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.

Authors:  Bangdong L Wei; Paul W Denton; Eduardo O'Neill; Tianci Luo; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation of in vivo replication from macrophage tropism.

Authors:  E D Miller; K M Duus; M Townsend; Y Yi; R Collman; M Reitz; L Su
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.

Authors:  Chien-Hsing Chang; Jorma Hinkula; Meiyu Loo; Tina Falkeborn; Rongxiu Li; Thomas M Cardillo; Edmund A Rossi; David M Goldenberg; Britta Wahren
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells.

Authors:  Sami Kukkonen; Maria Del Pilar Martinez-Viedma; Nayoung Kim; Mariana Manrique; Anna Aldovini
Journal:  Retrovirology       Date:  2014-04-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.